ASMB vs. NKTR, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRX
Should you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry.
Assembly Biosciences vs.
Nektar Therapeutics (NASDAQ:NKTR) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, community ranking, profitability, dividends, earnings and media sentiment.
75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 3.7% of Nektar Therapeutics shares are held by insiders. Comparatively, 5.1% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Nektar Therapeutics had 30 more articles in the media than Assembly Biosciences. MarketBeat recorded 31 mentions for Nektar Therapeutics and 1 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.86 beat Nektar Therapeutics' score of 0.41 indicating that Assembly Biosciences is being referred to more favorably in the news media.
Nektar Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.
Nektar Therapeutics received 394 more outperform votes than Assembly Biosciences when rated by MarketBeat users. Likewise, 70.78% of users gave Nektar Therapeutics an outperform vote while only 58.84% of users gave Assembly Biosciences an outperform vote.
Assembly Biosciences has lower revenue, but higher earnings than Nektar Therapeutics.
Nektar Therapeutics currently has a consensus target price of $4.92, suggesting a potential upside of 448.00%. Assembly Biosciences has a consensus target price of $35.00, suggesting a potential upside of 222.58%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Assembly Biosciences.
Assembly Biosciences has a net margin of -144.05% compared to Nektar Therapeutics' net margin of -180.70%. Assembly Biosciences' return on equity of -121.46% beat Nektar Therapeutics' return on equity.
Summary
Nektar Therapeutics beats Assembly Biosciences on 10 of the 17 factors compared between the two stocks.
Get Assembly Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assembly Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ASMB) was last updated on 3/19/2025 by MarketBeat.com Staff
